<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613976</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589H1101</org_study_id>
    <nct_id>NCT01613976</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients</brief_title>
  <official_title>A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (Vidaza®) in Adult Japanese Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and tolerability of oral panobinostat
      (PAN) in combination with a fixed dose of 5-Azacitidine (5-Aza) in adult Japanese patients
      with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid
      Leukemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicitiy(DLT)</measure>
    <time_frame>first 5 weeks of treatment period</time_frame>
    <description>DLT will be assessed during PK run-in period (up to 7 days) and 1st cycle (28 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter - Cmax</measure>
    <time_frame>Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿PK parameter - Tmax</measure>
    <time_frame>Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter - AUC (AUC0-48, AUC0-tlast)</measure>
    <time_frame>Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter - T1/2 (﻿apparent oral clearance, volume distribution)</measure>
    <time_frame>Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter - AUC0-inf</measure>
    <time_frame>Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough level of PAN in combination with 5-Aza</measure>
    <time_frame>Day 4, 5, 8 of the 1st cycle; pre-dose (0 hour)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿Frequency and severity of Adverse Events (AEs)</measure>
    <time_frame>Participants will be followed for the duration of treatment, an expected average of 6 months</time_frame>
    <description>Safety will be measured in terms of type, frequency and severity of adverse events according to CTCAE v4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory abnormalities</measure>
    <time_frame>duration of treatment, an expected average of 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Myelodysplastic Syndromes (MDS)</condition>
  <condition>Chronic Myelomonocytic Leukemia (CMML)</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Panobinostat and Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <arm_group_label>Panobinostat and Azacitidine</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Japanese patients who are candidates for treatment with 5-Aza and present with one of
             the following:

               -  intermediate-2 or high-risk MDS according to the International Prognostic Scoring
                  System (IPSS). OR

               -  AML with multilineage dysplasia and maximum of 30% blasts (former RAEB-T
                  according to FAB) OR CMML

          2. Patient has an ECOG performance status of ≤ 2

          3. Patients must have the following laboratory values unless elevations are considered
             due to MDS or leukemia: AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN; serum creatinine ≤ 1.5 x
             ULN; serum bilirubin (total and direct) ≤ 2 x ULN; electrolyte panel without
             clinically relevant abnormalities

        Exclusion Criteria:

          1. Patient who is planned for or has history of hematopoietic stem-cell transplantation
             (HSCT)

          2. Patients with relapsed/refractory AML

          3. Patient is receiving concurrent anti-cancer therapy

          4. Patient has received prior treatment with deacetylase inhibitors (DACi)

          5. Patient has received prior treatment with 5-Aza or 6-aza-2'-deoxycytidine (decitabine)

        7. Patient has shown suspected hypersensitivity to 5-Aza or Mannitol 8. Patients with
        impaired cardiac function 9. Patient taking medications with relative risk of prolonging
        the QT interval or inducing Torsade de pontes if such treatment cannot be discontinued or
        switched to a different medication prior to starting study treatment 10. Patients with
        clinical evidence of relevant mucosal or internal bleeding 11. Patient has any other
        concurrent severe and/or uncontrolled medical conditions

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>MDS</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <keyword>CMML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Panobinostat</keyword>
  <keyword>LBH589</keyword>
  <keyword>5-Aza</keyword>
  <keyword>Azacitidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

